Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin-dependent kinase 5 activator 1 (CDK5R1, also known as p35) is a neuron-specific regulatory subunit essential for the activation of cyclin-dependent kinase 5 (CDK5), a serine/threonine kinase critical for central nervous system development and function[1][3]. The p35 protein is cleaved by calpain to generate p25, a form that results in deregulated CDK5 activity and is implicated in neurodegenerative pathology; in particular, accumulation of p25 correlates with increased CDK5 activity and the hyperphosphorylation of tau protein observed in Alzheimer’s disease[1]. CDK5R1 is thus a key modulator of neuronal migration, synaptic plasticity, and has a central role in several brain diseases, mainly neurodegeneration and neurodevelopmental disorders[1][3].
For drugs targeting this pathway (e.g. CDK5 inhibitors): inhibition of CDK5 kinase activity by blocking either the kinase itself or interfering with its interaction with activators like p35/p25[3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin-dependent kinase 5 activator 1 (CDK5R1).